A
Alcista
Alcista · 25%BIIB
$140.81
Precio del escenario
$232.830
+4.005 (+1.72%)Al cierre
Loading chart…
- Máximo
- 234.200
- Apertura
- 228.990
- Precio medio ponderado por volumen
- 231.68
- Volumen
- 1.95M
- Capitalización
- 33.30B
- Mínimo
- 228.000
- Importe
- 451.15M
- EV/EBITDA, TTM
- 11.65
Biogen Inc. is a biotechnology company. The Company is focused on discovering, developing and delivering therapies. It has a portfolio of medicines to treat Multiple Sclerosis (MS), has introduced an approved treatment for Spinal Muscular Atrophy (SMA), co-developed treatments to address a defining pathology of Alzheimer's disease and launched an approved treatment to target a genetic cause of Amyotrophic Lateral Sclerosis (ALS). It markets a drug approved in United States, European Union and certain international markets for the treatment of Friedreich Ataxia (FA) in adults and adolescents aged 16 years and older. It is focused on advancing its pipeline in neurology, specialized immunology and rare diseases. Its marketed products include VUMERITY, TYSABRI, TECFIDERA, AVONEX and PLEGRIDY for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of FA, and QALSODY for the treatment of ALS. Its commercialized products also include EMPAVELI and SYFOVRE.
Análisis de IA of Biogen Inc. (BIIB)
ComprarBiogen Inc is a good buy right now due to its current price of $225.71, a strong forward P/E ratio of 13.947, and a significant year-to-date change of +26.93%. The recent RSI of 59.117 indicates bullish momentum, while the analyst price target suggests potential upside of 19.5% from the current price. However, the main risk is the insider selling activity, which has increased by 864.10% over the last month, indicating possible concerns among insiders.
Recomendaciones de analistas (32)
-12.19% Potencial de caída
Comprar
21 Comprar
11 Mantener
0 Vender
Actual: 232.83
Mínimo
143.00
Promedio
204.45
Máximo
246.00
BMO Capital
Market Perform
$220
2026-10-12
BMO Capital
2026-10-12
Precio objetivo
$220
Market Perform
JPMorgan
Sobreponderar
$300
2026-10-12
JPMorgan
2026-10-12
Precio objetivo
$300
Sobreponderar
UBS
Comprar
$270
2026-10-09
UBS
2026-10-09
Precio objetivo
$270
Comprar
HSBC
Reduce
$175
2026-09-10
HSBC
2026-09-10
Precio objetivo
$175
Reduce
Piper Sandler
Sobreponderar
$245
2026-09-03
Piper Sandler
2026-09-03
Precio objetivo
$245
Sobreponderar
Métricas de valoración
El PER previsto actual de Biogen Inc. (BIIB) es 13.95, frente a su media de 5 años de 13.62.
Escenarios de precio de Alphio AI para BIIB
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con BIIB en cartera
Cronología de eventos
Noticias
9.510-12stocktwitsJPMorgan Upgrades Biogen Rating and Price Target
2.010-12CNBCMemory Stocks Slide, eBay Soars on Upgrade
6.010-12CNBCMorgan Stanley Sees Growth Potential for eBay
6.010-12CNBCMultiple Companies See Stock Gains Following Analyst Upgrades
6.010-12CNBCJPMorgan Upgrades Biogen to Overweight Ahead of Key Data Releases
Preguntas frecuentes sobre BIIB, respondidas por Alphio AI
Biogen Inc. is a biotechnology company. The Company is focused on discovering, developing and delivering therapies. It has a portfolio of medicines to treat Multiple Sclerosis (MS), has introduced an approved treatment for Spinal Muscular Atrophy (SMA), co-developed treatments to address a defining pathology of Alzheimer's disease and launched an approved treatment to target a genetic cause of Amyotrophic Lateral Sclerosis (ALS). It markets a drug approved in United States, European Union and certain international markets for the treatment of Friedreich Ataxia (FA) in adults and adolescents aged 16 years and older. It is focused on advancing its pipeline in neurology, specialized immunology and rare diseases. Its marketed products include VUMERITY, TYSABRI, TECFIDERA, AVONEX and PLEGRIDY for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of FA, and QALSODY for the treatment of ALS. Its commercialized products also include EMPAVELI and SYFOVRE. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
Biogen Inc is a good buy right now due to its current price of $225.71, a strong forward P/E ratio of 13.947, and a significant year-to-date change of +26.93%. The recent RSI of 59.117 indicates bullish momentum, while the analyst price target suggests potential upside of 19.5% from the current price. However, the main risk is the insider selling activity, which has increased by 864.10% over the last month, indicating possible concerns among insiders.
32 analysts cover BIIB: 21 rate it Buy, 11 Hold and 0 Sell. The average price target is 204.45.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.